Vaginal dryness and dyspareunia
Senshio significantly decreases vaginal dryness and dyspareunia by 12 weeks vs. placebo1
The majority of women feel improvement in vaginal dryness and dyspareunia by 12 weeks from baseline1
Over 60% of women felt relief (no or mild symptoms) by 12 weeks1
Female Sexual Function Index (FSFI)
Greater improvements observed IN ALL SIX domains of the Female Sexual Function Index for Senshio vs. placebo4
A 12-week, multicentre, randomised, double-blind Phase III study in postmenopausal women, aged 40–80 years3 with VVA (n=919). Mean age: 58
Change from baseline in Total Score and in the domains of the FSFI (at Weeks 4 and 12) were included as secondary endpoints
Female Sexual Function Index: a 19-item questionnaire that assesses 6 domains of sexual function in women on a 6-point (0-5) scale. Higher scores indicate better sexual function.
Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.
Physiological Parameters of VVA
Senshio significantly improves vaginal physiology by 12 weeks vs. placebo2
A 12-week, multi-centre, randomised, double-blind, Phase III study in post-menopausal women ages 40-80 years, with VVA (n=826). Mean age: 58-59
Baseline values: Percentage of superficial cells: placebo: 0.9; Senshio 60mcg: 1.0; Percentage of parabasal cells: placebo: 38.5 ; Senshio 60mcg: 39.3; Vaginal pH: placebo: 6.3, Senshio 60mcg: 6.4. Adapted from Bachmann, 20102.
References:
- Bruyniks N, et al. Climacteric 2015; 19(1): 60-65.
- Bachmann G, et al. Menopause 2010; 17: 480-486.
- Portman D, et al. Maturitas 2014; 78: 91–98.
- Constantine G, et al. Climacteric 2015; 18: 226-232.